1
|
Lv J, Hu Y, Li L, He Y, Wang J, Guo N, Fang Y, Chen Q, Cai C, Tong J, Tang L, Wang Z. Targeting FABP4 in elderly mice rejuvenates liver metabolism and ameliorates aging-associated metabolic disorders. Metabolism 2023; 142:155528. [PMID: 36842611 DOI: 10.1016/j.metabol.2023.155528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 02/06/2023] [Accepted: 02/20/2023] [Indexed: 02/28/2023]
Abstract
INTRODUCTION Aging is characterized by progressive metabolic dyshomeostasis that increases morbidity and mortality. Solutions for optimizing healthy aging are challenged by lacking appropriate biomarkers. Moreover, druggable targets to rejuvenate the aging-associated metabolic phenotypes remain unavailable. METHODS Proteomics analysis was performed in a cohort of young and elderly adults. Circulating levels of insulin-like growth factor 1 (IGF-1) and fatty acid binding protein 4 (FABP4) were evaluated by ELISA. FABP4 was silenced in elderly mice by adeno-associated virus. Metabolic activities were measured by metabolic cages. Cognitive function was evaluated by Morris water maze. Glucose and lipid metabolism were evaluated by biochemistry assays with blood samples. RNA-seq in mouse liver was performed for transcriptome analysis. RESULTS Among 9 aging-sensitive proteins shared by both male and female, FABP4 was identified as a reliable aging biomarker in both human and mouse. Silencing FABP4 in elderly mice significantly rejuvenated the aging-associated decline in metabolic activities. FABP4 knockdown reversed the aging-associated metabolic disorders by promoting degradation of cholesterol and fatty acids, while suppressing gluconeogenesis. Transcriptome analysis revealed a restoration of the pro-aging gene reprogramming towards inflammation and metabolic disorders in the liver after FABP4 knockdown. FABP4 overexpression promoted human LO2 cell senescence. Moreover, administration of an FABP4 inhibitor BMS309403 delivered metabolic benefits in elderly mice. CONCLUSION Our findings demonstrate FABP4 as a reliable aging biomarker as well as a practicable target to improve healthy aging in the elderly.
Collapse
Affiliation(s)
- Jian Lv
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen 518057, China; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yimeng Hu
- Department of Endocrinology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China; Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
| | - Lili Li
- Central Laboratory, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Yuan He
- Central Laboratory, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Jingjing Wang
- School of Martial Arts, Wuhan Sports University, Wuhan 430079, China
| | - Ningning Guo
- Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen 518057, China; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yu Fang
- Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen 518057, China; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qin Chen
- School of Life Sciences, Central China Normal University, Wuhan 430079, China
| | - Cheguo Cai
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
| | - Jingjing Tong
- School of Life Sciences, Central China Normal University, Wuhan 430079, China.
| | - Lixu Tang
- School of Martial Arts, Wuhan Sports University, Wuhan 430079, China.
| | - Zhihua Wang
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen 518057, China; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
| |
Collapse
|
2
|
Abstract
Human lifespan has increased significantly in the last 200 years, emphasizing our need to age healthily. Insights into molecular mechanisms of aging might allow us to slow down its rate or even revert it. Similar to aging, glycosylation is regulated by an intricate interplay of genetic and environmental factors. The dynamics of glycopattern variation during aging has been mostly explored for plasma/serum and immunoglobulin G (IgG) N-glycome, as we describe thoroughly in this chapter. In addition, we discuss the potential functional role of agalactosylated IgG glycans in aging, through modulation of inflammation level, as proposed by the concept of inflammaging. We also comment on the potential to use the plasma/serum and IgG N-glycome as a biomarker of healthy aging and on the interventions that modulate the IgG glycopattern. Finally, we discuss the current knowledge about animal models for human plasma/serum and IgG glycosylation and mention other, less explored, instances of glycopattern changes during organismal aging and cellular senescence.
Collapse
|
3
|
Novel ageing-biomarker discovery using data-intensive technologies. Mech Ageing Dev 2015; 151:114-21. [PMID: 26056714 DOI: 10.1016/j.mad.2015.05.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Revised: 05/01/2015] [Accepted: 05/28/2015] [Indexed: 12/23/2022]
Abstract
Ageing is accompanied by many visible characteristics. Other biological and physiological markers are also well-described e.g. loss of circulating sex hormones and increased inflammatory cytokines. Biomarkers for healthy ageing studies are presently predicated on existing knowledge of ageing traits. The increasing availability of data-intensive methods enables deep-analysis of biological samples for novel biomarkers. We have adopted two discrete approaches in MARK-AGE Work Package 7 for biomarker discovery; (1) microarray analyses and/or proteomics in cell systems e.g. endothelial progenitor cells or T cell ageing including a stress model; and (2) investigation of cellular material and plasma directly from tightly-defined proband subsets of different ages using proteomic, transcriptomic and miR array. The first approach provided longitudinal insight into endothelial progenitor and T cell ageing. This review describes the strategy and use of hypothesis-free, data-intensive approaches to explore cellular proteins, miR, mRNA and plasma proteins as healthy ageing biomarkers, using ageing models and directly within samples from adults of different ages. It considers the challenges associated with integrating multiple models and pilot studies as rational biomarkers for a large cohort study. From this approach, a number of high-throughput methods were developed to evaluate novel, putative biomarkers of ageing in the MARK-AGE cohort.
Collapse
|
4
|
Bürkle A, Moreno-Villanueva M, Bernhard J, Blasco M, Zondag G, Hoeijmakers JHJ, Toussaint O, Grubeck-Loebenstein B, Mocchegiani E, Collino S, Gonos ES, Sikora E, Gradinaru D, Dollé M, Salmon M, Kristensen P, Griffiths HR, Libert C, Grune T, Breusing N, Simm A, Franceschi C, Capri M, Talbot D, Caiafa P, Friguet B, Slagboom PE, Hervonen A, Hurme M, Aspinall R. MARK-AGE biomarkers of ageing. Mech Ageing Dev 2015; 151:2-12. [PMID: 25818235 DOI: 10.1016/j.mad.2015.03.006] [Citation(s) in RCA: 148] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 03/19/2015] [Accepted: 03/21/2015] [Indexed: 01/29/2023]
Abstract
Many candidate biomarkers of human ageing have been proposed in the scientific literature but in all cases their variability in cross-sectional studies is considerable, and therefore no single measurement has proven to serve a useful marker to determine, on its own, biological age. A plausible reason for this is the intrinsic multi-causal and multi-system nature of the ageing process. The recently completed MARK-AGE study was a large-scale integrated project supported by the European Commission. The major aim of this project was to conduct a population study comprising about 3200 subjects in order to identify a set of biomarkers of ageing which, as a combination of parameters with appropriate weighting, would measure biological age better than any marker in isolation.
Collapse
Affiliation(s)
- Alexander Bürkle
- Molecular Toxicology Group, Department of Biology, Box 628, University of Konstanz, 78457 Konstanz, Germany.
| | - María Moreno-Villanueva
- Molecular Toxicology Group, Department of Biology, Box 628, University of Konstanz, 78457 Konstanz, Germany
| | | | - María Blasco
- Spanish National Cancer Research Centre (CNIO), 3 Melchor Fernandez Almagro, 28029 Madrid, Spain
| | | | - Jan H J Hoeijmakers
- Department of Genetics, Erasmus University Medical Center, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Olivier Toussaint
- University of Namur, Research Unit on Cellular Biology, Rue de Bruxelles, 61, Namur B-5000, Belgium
| | - Beatrix Grubeck-Loebenstein
- Research Institute for Biomedical Aging Research, University of Innsbruck, Rennweg, 10, 6020 Innsbruck, Austria
| | - Eugenio Mocchegiani
- Translational Research Center of Nutrition and Ageing, IRCCS-INRCA, Via Birarelli 8, 60121 Ancona, Italy
| | - Sebastiano Collino
- Nestlé Institute of Health Sciences SA, Molecular Biomarkers, EPFL Innovation Park, 1015 Lausanne, Switzerland
| | - Efstathios S Gonos
- National Hellenic Research Foundation, Institute of Biology, Medicinal Chemistry and Biotechnology, Athens, Greece
| | - Ewa Sikora
- Laboratory of the Molecular Bases of Ageing, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur street, 02-093 Warsaw, Poland
| | - Daniela Gradinaru
- Ana Aslan - National Institute of Gerontology and Geriatrics, Bucharest, Romania
| | - Martijn Dollé
- National Institute for Public Health and the Environment (RIVM), Centre for Prevention and Health Services Research, P.O. Box 1, 3720 BA Bilthoven, The Netherlands
| | - Michel Salmon
- Straticell, Science Park Crealys, Rue Jean Sonet 10, 5032 Les Isnes, Belgium
| | - Peter Kristensen
- Department of Engineering - BCE Protein Engineering, Gustav Wiedsvej 10, 8000 Aarhus, Denmark
| | - Helen R Griffiths
- Life and Health Sciences, Aston Research Centre for Healthy Ageing, Aston University, Birmingham, UK
| | - Claude Libert
- Department for Molecular Biomedical Research, VIB, Ghent, Belgium
| | - Tilman Grune
- Institute of Nutritional Medicine, University of Hohenheim, 70593 Stuttgart, Germany; Department of Nutritional Toxicology, Friedrich Schiller University Jena, Dornburger Str. 24, 07743 Jena, Germany
| | - Nicolle Breusing
- Institute of Nutritional Medicine, University of Hohenheim, 70593 Stuttgart, Germany
| | - Andreas Simm
- Department of Cardiothoracic Surgery, University Hospital Halle, Ernst-Grube Str. 40, 06120 Halle (Saale), Germany
| | - Claudio Franceschi
- CIG-Interdepartmental Center "L.Galvani", Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy
| | - Miriam Capri
- CIG-Interdepartmental Center "L.Galvani", Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy
| | | | - Paola Caiafa
- Department of Cellular Biotechnologies and Hematology, Faculty of Pharmacy and Medicine, "Sapienza" University Rome, V.le Regina Elena 324, 00161 Rome, Italy
| | - Bertrand Friguet
- Sorbonne Universités, UPMC Univ Paris 06, UMR UPMC CNRS 8256, Biological adaptation and ageing - IBPS, INSERM U1164, F-75005 Paris, France
| | - P Eline Slagboom
- Department of Molecular Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
| | - Antti Hervonen
- Medical School, University of Tampere, 33014 Tampere, Finland
| | - Mikko Hurme
- Medical School, University of Tampere, 33014 Tampere, Finland
| | | |
Collapse
|
5
|
Griffiths HR, Dias IHK, Willetts RS, Devitt A. Redox regulation of protein damage in plasma. Redox Biol 2014; 2:430-5. [PMID: 24624332 PMCID: PMC3949090 DOI: 10.1016/j.redox.2014.01.010] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2013] [Accepted: 01/11/2014] [Indexed: 01/12/2023] Open
Abstract
The presence and concentrations of modified proteins circulating in plasma depend on rates of protein synthesis, modification and clearance. In early studies, the proteins most frequently analysed for damage were those which were more abundant in plasma (e.g. albumin and immunoglobulins) which exist at up to 10 orders of magnitude higher concentrations than other plasma proteins e.g. cytokines. However, advances in analytical techniques using mass spectrometry and immuno-affinity purification methods, have facilitated analysis of less abundant, modified proteins and the nature of modifications at specific sites is now being characterised. The damaging reactive species that cause protein modifications in plasma principally arise from reactive oxygen species (ROS) produced by NADPH oxidases (NOX), nitric oxide synthases (NOS) and oxygenase activities; reactive nitrogen species (RNS) from myeloperoxidase (MPO) and NOS activities; and hypochlorous acid from MPO. Secondary damage to proteins may be caused by oxidized lipids and glucose autooxidation. In this review, we focus on redox regulatory control of those enzymes and processes which control protein maturation during synthesis, produce reactive species, repair and remove damaged plasma proteins. We have highlighted the potential for alterations in the extracellular redox compartment to regulate intracellular redox state and, conversely, for intracellular oxidative stress to alter the cellular secretome and composition of extracellular vesicles. Through secreted, redox-active regulatory molecules, changes in redox state may be transmitted to distant sites. Loss of redox homeostasis may affect the secretome content and protein concentration, transmitting redox signals to distant cells through extracellular vesicles. Damaged glycoforms may arise from oxidants or aberrant biosynthetic regulation. Reactive species generation by NOX and NOS is controlled through redox regulation. Cell surface and plasma thiol-oxidised proteins can be reduced and their activity modulated by thioredoxin, protein disulphide isomerase and reductases.
Collapse
Key Words
- Ageing
- BH4, tetrahydrobiopterin
- COX, cyclo-oxygenase
- CRP, C-reactive protein
- ER, endoplasmic reticulum
- ERO1, endoplasmic reticulum oxidoreductin 1
- EV, extracellular vesicles
- FX1, factor XI
- GPI, glycoprotein 1
- GPX, glutathione peroxidase
- GRX, glutaredoxin
- GSH, glutathione
- Glycosylation
- MIRNA, microRNA
- MPO, myeloperoxidase
- NO, nitric oxide
- NOS, nitric oxide synthase
- NOX, NADPH oxidase
- Nitration
- O2•−, superoxide anion radical
- ONOO-, peroxynitrite
- Oxidation
- PDI, protein disulphide isomerase
- Peroxiredoxin
- Prx, peroxiredoxin
- RNS, reactive nitrogen species
- ROS, reactive nitrogen species
- Thioredoxin
- Trx, thioredoxin
- VWF, von Willebrand factor
- XO, xanthine oxidase
Collapse
Affiliation(s)
- Helen R Griffiths
- Life & Health Sciences and Aston Research Centre for Healthy Ageing, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | - Irundika H K Dias
- Life & Health Sciences and Aston Research Centre for Healthy Ageing, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | - Rachel S Willetts
- Life & Health Sciences and Aston Research Centre for Healthy Ageing, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | - Andrew Devitt
- Life & Health Sciences and Aston Research Centre for Healthy Ageing, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| |
Collapse
|